Effect of Galantamine on Inflammation and Cognition

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This study tests whether galantamine (GAL) reduces HIV-related inflammation and cognitive deficits. In this double-blind placebo-controlled crossover study, HIV-infected individuals (N=120; 60 smokers and 60 non-smokers) will be randomized to 12 weeks of GAL or placebo, followed by a 4-week washout, then 12 weeks of GAL or placebo (arms switched). Outcomes are monocyte/macrophage and T cell activation and neurocognitive performance.
Epistemonikos ID: 3549bef204b219d91e5bd66f3b591e989737ddba
First added on: May 21, 2024